Skip to content

The Value of Placental Vascularization and Placental Volume in Pregnancy in APLS

TheValue of Placental Vascularization Indices and Placental Volume in Pregnancies With Antiphospholipid Syndrome for Prediction of Neonatal Outcome

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03505840
Enrollment
100
Registered
2018-04-23
Start date
2018-04-24
Completion date
2020-10-10
Last updated
2020-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antiphospholipid Syndrome in Pregnancy

Brief summary

Antiphospholipid antibodies are autoantibodies directed against phospholipid-binding proteins. Among these groups of antibodies, lupus anticoagulant (LA) and anticardiolipin antibodies (aCL)

Detailed description

APLS can be primary when no evidence of autoimmune disease is found, or secondary to autoimmune processes like systemic lupus erythematous (SLE) in a 40% of the cases.

Interventions

DIAGNOSTIC_TESTUltrasound with Doppler and 3D technology

ultrasound will be made to pregnant females in 3rd trimester with doppler and 3D technology

Sponsors

Cairo University
CollaboratorOTHER
Aljazeera Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Singleton pregnancy. * Gestational age of 34-37 weeks. * Pregnant women with antiphospholipid syndrome

Exclusion criteria

* Twin or multiple pregnancies. * Congenital fetal anomalies. * Gestational age of less than 34. * Gestational age of more than 37. * Women with placental or umbilical artery anomalies. * Antepartum hemorrhage (placental abruption, placenta previa and vasa previa). * Posterior placenta. * History of rupture of membrane. * Patient refusal or fall outs.

Design outcomes

Primary

MeasureTime frame
The number of participants who will have impaired placental doppler indiceswithin 2 months

Countries

Egypt

Contacts

Primary ContactMahmoud Alalfy
mahmoudalalfy@ymail.com01002611058

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026